» Articles » PMID: 20578910

Antiretroviral Use Among Active Injection-drug Users: the Role of Patient-provider Engagement and Structural Factors

Overview
Date 2010 Jun 29
PMID 20578910
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

HIV-seropositive, active injection-drug users (IDUs), compared with other HIV populations, continue to have low rates of highly active antiretroviral therapy (HAART) use, contributing to disparities in their HIV health outcomes. We sought to identify individual-level, interpersonal, and structural factors associated with HAART use among active IDUs to inform comprehensive, contextually tailored intervention to improve the HAART use of IDUs. Prospective data from three semiannual assessments were combined, and logistic general estimating equations were used to identify variables associated with taking HAART 6 months later. Participants were a community sample of HIV-seropositive, active IDUs enrolled in the INSPIRE study, a U.S. multisite (Baltimore, Miami, New York, San Francisco) prevention intervention. The analytic sample included 1,225 observations, and comprised 62% males, 75% active drug users, 75% non-Hispanic blacks, and 55% with a CD4 count <350; 48% reported HAART use. Adjusted analyses indicated that the later HAART use of IDUs was independently predicted by patient-provider engagement, stable housing, medical coverage, and more HIV primary care visits. Significant individual factors included not currently using drugs and a positive attitude about HAART benefits even if using illicit drugs. Those who reported patient-centered interactions with their HIV primary care provider had a 45% greater odds of later HAART use, and those with stable housing had twofold greater odds. These findings suggest that interventions to improve the HIV treatment of IDUs and to reduce their HIV health disparities should be comprehensive, promoting better patient-provider engagement, stable housing, HAART education with regard to illicit drug use, and integration of drug-abuse treatment with HIV primary care.

Citing Articles

Patient-centered Engagement as a Mediator in the Associations of Healthcare Discrimination, Pain Care Denial, and Later Substance Use Among a Sample of Predominately African Americans Living with HIV.

Tseng T, Mitchell M, Chander G, Latkin C, Kennedy C, Knowlton A AIDS Behav. 2023; 28(2):429-438.

PMID: 38060111 DOI: 10.1007/s10461-023-04235-5.


Barriers and facilitators to primary care engagement for people who inject drugs: A systematic review.

Heidari O, Tormohlen K, Dangerfield 2nd D, Tobin K, Farley J, Aronowitz S J Nurs Scholarsh. 2022; 55(3):605-622.

PMID: 36480158 PMC: 10635283. DOI: 10.1111/jnu.12863.


Injection and Non-Injection Drug Use Among Adults with Diagnosed HIV in the United States, 2015-2018.

Wu K, Tie Y, Dasgupta S, Beer L, Marcus R AIDS Behav. 2021; 26(4):1026-1038.

PMID: 34536178 PMC: 8930780. DOI: 10.1007/s10461-021-03457-9.


HIV-positive persons who inject drugs experience poor health outcomes and unmet needs for care services.

Dasgupta S, Tie Y, Lemons-Lyn A, Broz D, Buchacz K, Shouse R AIDS Care. 2020; 33(9):1146-1154.

PMID: 32985227 PMC: 8628508. DOI: 10.1080/09540121.2020.1826396.


Acceptability of a hypothetical preventative HIV vaccine among people who use drugs in Vancouver, Canada.

Fleming T, Valleriani J, Ng C, Maher L, Small W, McNeil R BMC Public Health. 2020; 20(1):1081.

PMID: 32646390 PMC: 7350753. DOI: 10.1186/s12889-020-09202-6.


References
1.
Carrieri M, Chesney M, Spire B, Loundou A, Sobel A, Lepeu G . Failure to maintain adherence to HAART in a cohort of French HIV-positive injecting drug users. Int J Behav Med. 2003; 10(1):1-14. DOI: 10.1207/s15327558ijbm1001_01. View

2.
DiMatteo M . Social support and patient adherence to medical treatment: a meta-analysis. Health Psychol. 2004; 23(2):207-18. DOI: 10.1037/0278-6133.23.2.207. View

3.
Purcell D, Metsch L, Latka M, Santibanez S, Gomez C, Eldred L . Interventions for seropositive injectors-research and evaluation: an integrated behavioral intervention with HIV-positive injection drug users to address medical care, adherence, and risk reduction. J Acquir Immune Defic Syndr. 2004; 37 Suppl 2:S110-8. DOI: 10.1097/01.qai.0000140609.44016.c4. View

4.
Mizuno Y, Purcell D, Zhang J, Knowlton A, De Varona M, Arnsten J . Predictors of current housing status among HIV-seropositive injection drug users (IDUs): results from a 1-year study. AIDS Behav. 2008; 13(1):165-72. DOI: 10.1007/s10461-008-9364-6. View

5.
Korthuis P, Josephs J, Fleishman J, Hellinger J, Himelhoch S, Chander G . Substance abuse treatment in human immunodeficiency virus: the role of patient-provider discussions. J Subst Abuse Treat. 2008; 35(3):294-303. PMC: 2574740. DOI: 10.1016/j.jsat.2007.11.005. View